Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL16192514 | 0.98 | CA2 (0.46) | CA2ALDH1A1HSPD1BLMHSPE1 | |
| Ammonia Solution, Strong SCHEMBL16192510 | 0.98 | CA2 (0.46) | CA2ALDH1A1HSPD1BLMHSPE1 | |
| SCHEMBL2802518 | 0.98 | CA2 (0.46) | CA2ALDH1A1HSPD1BLMHSPE1 | |
| SCHEMBL430002 | 0.86 | HSPD1 (0.51) | HSPD1BLMHSPE1 | |
| SCHEMBL11355584 | 0.86 | CA2 (0.50) | CA2ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL3740917 | 0.85 | CYP2D6 (0.39) | ALDH1A1HSPD1BLMHSPE1TSHR | |
| SCHEMBL15577120 | 0.85 | HSPD1 (0.46) | HSPD1BLMHSPE1 | |
| SCHEMBL5157975 | 0.84 | CA2 (0.49) | CA2ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL17241161 | 0.84 | CA2 (0.42) | CA2ALDH1A1HSPD1BLMHSPE1 | |
| SCHEMBL1702351 | 0.83 | CA2 (0.49) | CA2ALDH1A1TSHRCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240407982-A1 | Personal Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2024-12-12 | — | — | US | claimed |
| US-12064501-B2 | Personal care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2024-08-20 | — | — | US | claimed |
| US-20230320952-A1 | Personal Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2023-10-12 | — | — | US | claimed |
| WO-2023196568-A1 | PERSONAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4257111-A1 | PERSONAL CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3438083-B1 | ALKOXY MAGNESIUM, METHOD FOR PRODUCING ALKOXY MAGNESIUM, SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION USE, CATALYST FOR OLEFIN POLYMERIZATION USE, AND METHOD FOR PRODUCING OLEFIN POLYMER | TOHO TITANIUM CO LTD (JP) | 2023-08-16 | — | — | EP | claimed |
| EP-2721100-B1 | ENVIRONMENTALLY FRIENDLY COALESCING AGENTS | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2020-08-19 | — | — | EP | claimed |
| WO-2019198923-A1 | MICROSTRUCTURE FOR TRANSCUTANEOUS AND INTRACUTANEOUS DRUG DELIVERY OF CYCLOSPORIN A (CSA) | 가천대학교 산학협력단 | 2019-10-17 | — | — | WO | claimed |
| EP-3035907-B1 | COSMETIC COMPOSITION COMPRISING AMINO SILICONES, CATIONIC SURFACTANTS AND SPECIFIC ESTERS AND A PROCESS FOR A COSMETIC TREATMENT | OREAL (FR) | 2019-04-03 | — | — | EP | claimed |
| EP-3438083-A1 | ALKOXY MAGNESIUM, METHOD FOR PRODUCING ALKOXY MAGNESIUM, SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION USE, CATALYST FOR OLEFIN POLYMERIZATION USE, AND METHOD FOR PRODUCING OLEFIN POLYMER | Toho Titanium Co., Ltd. (JP) | 2019-02-06 | — | — | EP | claimed |
| WO-2004052340-A1 | MICROPARTICLES PREPARED USING AN IONIC LIQUID | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | claimed |
| EP-1155688-B1 | Use in cosmetics of at least a organopolysiloxane as a gelling agent and a cosmetic composition containing said product | OREAL (FR) | 2003-07-23 | — | — | EP | claimed |
| EP-1035862-B1 | CYCLOSPORIN-CONTAINING MICROEMULSION PRECONCENTRATE COMPOSITION | CHONG KUN DANG PHARM CORP (KR) | 2003-07-09 | — | — | EP | claimed |
| US-20030060402-A1 | Novel cyclosporin galenic forms | CAVANAK THOMAS (CH) | 2003-03-27 | — | — | US | claimed |
| US-20020013272-A1 | Novel cyclosporin galenic forms | CAVANAK THOMAS (CH) | 2002-01-31 | — | — | US | claimed |
| US-6326013-B1 | TRANSFER-RESISTANT MAKE-UP | L'OREAL (FR) | 2001-12-04 | — | — | US | claimed |
| EP-1035862-A2 | CYCLOSPORIN-CONTAINING MICROEMULSION PRECONCENTRATE COMPOSITION | CHONG KUN DANG CORP (KR) | 2000-09-20 | — | — | EP | claimed |
| US-6063762-A | CYCLOSPORIN MICROEMULSION WITH OILS, SOLVENTS AND SURFACTANTS | CHONG KUN DANG CORP. (KR) | 2000-05-16 | — | — | US | claimed |
| US-6028067-A | AS IMMUNOSUPPRESSANT | CHONG KUN DANG CORP. (KR) | 2000-02-22 | — | — | US | claimed |
| WO-1999000002-A2 | CYCLOSPORIN-CONTAINING MICROEMULSION PRECONCENTRATE COMPOSITION | CHONG KUN DANG CORP. (KR) | 1999-01-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013272-A1 | Novel cyclosporin galenic forms | MALT1, LTA, TMSB10 | CA2 2900/4885ALDH1A1 4495/4885HSPD1 2214/4885 |
| US-20030060402-A1 | Novel cyclosporin galenic forms | MALT1, LTA, TMSB10 | CA2 2900/4885ALDH1A1 4495/4885HSPD1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.